108502 20230519145353.0 doi 10.1080/03007995.2020.1847718 sideral 121669 ART-2021-121669 eng McMahon, S.B. The burden of musculoskeletal pain and the role of topical non-steroidal anti-inflammatory drugs (NSAIDs) in its treatment. Ten underpinning statements from a global pain faculty 2021 Access copy available to the general public Unrestricted This document presents the conclusions of a detailed discussion on the role of topical NSAIDs during a round table Global Pain Faculty meeting held in Amsterdam in 2019 and subsequent discussions online. The aim of this evidence-based document is to describe the impact of musculoskeletal pain both in terms of the large numbers of sufferers and its economic impact. The document considers the place of topical therapies alongside other pharmacological and non-pharmacological treatments and presents the evidence for the benefits and harms of topical NSAIDS including indicators of efficacy for three main topical NSAIDs– diclofenac, ibuprofen and ketoprofen–based on almost 15, 000 participants in randomized controlled trials for acute and chronic musculoskeletal pain. These topical NSAIDs have the largest body of evidence. For acute pain, numbers needed to treat to achieve at least 50% reduction in pain are as follows with 95% confidence intervals in brackets: Diclofenac emulgel 1.8(1.5–2.1) (5170 participants), Ibuprofen gel 2.7 (1.7–4.2) (436 participants), Ketoprofen gel 2.2 (1.7–2.8) (683 participants). For chronic pain, the NNTs are Diclofenac any formulation 9.5(7–14) (5995 participants). Ketoprofen 6.9(5.5–9.3) (2573 participants). Randomized controlled trial evidence suggests that adverse events for active topical NSAIDs are similar to placebo. Finally the gaps in knowledge are considered with suggestions on how further research might help. The global pain faculty was brought together by GSK under an unrestricted educational grant. info:eu-repo/semantics/openAccess All rights reserved http://www.europeana.eu/rights/rr-f/ 2.705 2021 MEDICINE, GENERAL & INTERNAL 94 / 172 = 0.547 2021 Q3 T2 MEDICINE, RESEARCH & EXPERIMENTAL 107 / 140 = 0.764 2021 Q4 T3 0.689 2021 Medicine (miscellaneous) 2021 Q2 4.0 2021 info:eu-repo/semantics/article info:eu-repo/semantics/acceptedVersion Dargan, P. Lanas, A. Universidad de Zaragoza (orcid)0000-0001-5932-2889 Wiffen, P. 1007 610 Universidad de Zaragoza Dpto. Medicina, Psiqu. y Derm. Area Medicina 37, 2 (2021), 287-292 Curr. med. res. opin. CURRENT MEDICAL RESEARCH AND OPINION 0300-7995 536221 http://zaguan.unizar.es/record/108502/files/texto_completo.pdf Postprint 980867 http://zaguan.unizar.es/record/108502/files/texto_completo.jpg?subformat=icon icon Postprint oai:zaguan.unizar.es:108502 articulos driver 2023-05-18-13:28:15 ARTICLE